Immunomedics (IMMU) Soars After an Update Regarding its ADC programs
June 28, 2013 at 09:49 AM EDT
Shares of biotech Immunomedics (IMMU) soared 16% at the end of last week, defying the slumping market, after the company provided a long-awaited clinical update regarding its antibody-drug conjugate (ADC) programs. ADCs are considered a crucial piec... Read the rest of Immunomedics (IMMU) Soars After an Update Regarding its ADC programs at InvestorGuide.com .
